SUBLOCADE®
Opioid Use Disorder
MarketedCommercial
Key Facts
About Indivior PLC
Indivior is a mission-driven, publicly traded biopharmaceutical company dedicated to saving lives from the devastating impacts of substance use disorders and mental illness. Its strategic foundation is built upon a 25-year legacy of innovation in buprenorphine-based medication-assisted treatment (MAT), most notably through the commercialization of SUBLOCADE®, a once-monthly injectable that has become the standard of care. Following a strategic redomiciliation to the U.S. and resolution of legacy legal matters, the company is now executing a focused growth strategy to defend its core OUD franchise while advancing a promising pipeline targeting schizophrenia and cocaine use disorder.
View full company profileTherapeutic Areas
Other Opioid Use Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| TRV734 | Trevena | Phase 1 |
| FP-004 (SIF Formulation) | Foresee Pharmaceuticals | Preclinical |
| Safer Ibogaine Analogs | Gilgamesh Pharmaceuticals | Pre-clinical/Research |
| AM-510 | Aion Medicines | Discovery |
| Naltrexone Implant | Delpor | Phase 1 |
| Platform Expansion | Amygdala Neurosciences | Research |
| Undisclosed OUD Program | Epiodyne | Pre-clinical |
| AQL™-Naltrexone | Plumb Pharmaceuticals | Pre-clinical |
| MEB-1170 | Mebias Discovery | Phase 1 |